News Augustine decloaks with $85m for nerve disease programme Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.
News Sofinnova closes new fund and backs a trio of new biotechs Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.
Oncology A quarter of cancer patients don’t respond to targeted thera... The more progress we make in precision medicine, the more edge cases we discover.
News Sofinnova raises €1.2bn to back 'up to 60' companies Sofinnova has raised €1.2bn that it says could support 50 to 60 companies across biotech, medtech, industrial biotech, and digital medicine.
News Perlmutter's Eikon raises $351m in major financing round Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.